Wockhardt Ltd - Stock Valuation and Financial Performance

BSE: 532300 | NSE: WOCKPHARMA | Pharmaceuticals & Drugs | Small Cap

Wockhardt Share Price

565.80 -10.55 -1.83%
as on 12-Apr'24 10:20

DeciZen - make an informed investing decision on Wockhardt

Overall Rating
Bole Toh

1. Quality

2. Valuation


3. Price Trend

Wockhardt stock performance -

mw4me loader
P/E Ratio (CD):
Market Cap:
8,841.3 Cr.
52-wk low:
52-wk high:

Is Wockhardt Ltd an attractive stock to invest in?

1. Is Wockhardt Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Wockhardt Ltd is a below average quality company.

2. Is Wockhardt Ltd undervalued or overvalued?

The key valuation ratios of Wockhardt Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Wockhardt Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Wockhardt Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Wockhardt:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Wockhardt Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 13.3%8.8%5.5%-0.8%-3.6%-1.3%0.2%-1.5%1.4%-3.8%-
Value Creation

Growth Parameters

Growth Parameters Colour Code Guide

Sales 4,8304,4824,4534,0153,9373,5662,8442,7083,2302,6512,776
Sales YoY Gr.--7.2%-0.6%-9.9%-1.9%-9.4%-20.2%-4.8%19.3%-17.9%-
Adj EPS 53.339.221.8-17.9-37.1-22.6-14.9-22-8.6-29.8-32.7
YoY Gr.--26.6%-44.3%-182.1%NANANANANANA-
BVPS (₹) 271.8282.2312.4275.1234.5220219.8280.5266231.8229.4
Adj Net
Cash Flow from Ops. 1,47635571.6-26968.4183649-287413153-
Debt/CF from Ops. 1.35.737.4-15.454.818.45-8.14.512.3-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -6.5%-7.6%-2.3%-17.9%
Adj EPS -193.8%NANANA
Share Price -0.6% 6.5% 12.4% 234.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on
Equity %
Op. Profit
Mgn %
Net Profit
Mgn %
Debt to
Working Cap
Cash Conv.

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.57

Return on Equity is Poor

Sales growth has been subdued in last 3 years -2.32%

Sales growth is not so good in last 4 quarters at 5.74%

Latest Financials - Wockhardt Ltd.

Standalone Consolidated
TTM EPS (₹) -38.8 -32.7
TTM Sales (₹ Cr.) 1,090 2,776
BVPS (₹.) 126.3 229.4
Reserves (₹ Cr.) 1,861 3,442
P/BV 4.56 2.51
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 162.45 / 630.00
All Time Low / High (₹) 62.20 / 1996.06
Market Cap (₹ Cr.) 8,841
Equity (₹ Cr.) 76.7
Face Value (₹) 5
Industry PE 48.7

Management X-Ray of Wockhardt:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *41.9947.3243.6047.8452.7756.0865.4669.0864.3874.51
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Wockhardt

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Operating Expenses 3,8513,7723,9594,0023,9923,6042,7462,7712,9322,550
Manufacturing Costs333349366290213247206227267229
Material Costs1,8061,4871,6141,6621,7981,6361,2031,1351,2671,111
Employee Cost 769869951967937800743763749637
Other Costs 9431,0671,0281,0841,045921593646649573
Operating Profit 98070949413-55-3898-63298101
Operating Profit Margin (%) 20.3%15.8%11.1%0.3%-1.4%-1.1%3.4%-2.3%9.2%3.8%
Other Income 846766114177216013220122
Interest 8355129225255265276249299302
Depreciation 140145142149150164224246247251
Exceptional Items 50000-35800-142-183-294
Profit Before Tax 891575289-247-641-447-342-568-411-624
Tax 4816338-2126-135-204-271-132-3
Profit After Tax 843413252-226-667-312-138-297-279-621
PAT Margin (%) 17.4%9.2%5.6%-5.6%-16.9%-8.7%-4.9%-11.0%-8.6%-23.4%
Adjusted EPS (₹)58.933.920.9-16.3-50.7-16.2-5.857.5-16.9-38.8
Dividend Payout Ratio (%)16%54%0%-56%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)

Equity and Liabilities

Shareholders Fund 3,5363,6693,7463,3002,8152,6432,6423,3483,8313,338
Share Capital 3533545555555555557272
Reserves 3,1833,3163,6913,2442,7602,5872,5863,2933,7593,266
Minority Interest136144465382346330386383353308
Long Term Debt1,1021,1851,9213,1902,1731,8911,241503355224
Short Term Debt2103485506634375629041,0661,0341,330
Trade Payables558553638534602840895696921867
Others Liabilities 1,0791,6066567801,6051,3051,6821,3801,1761,008
Total Liabilities 6,6227,5057,9768,8497,9787,5717,7497,3767,6707,075

Fixed Assets

Gross Block4,6434,5534,3775,4565,7726,1136,7035,6566,0195,696
Accumulated Depreciation2,3482,4301,5682,6842,8843,0553,2012,3132,5572,621
Net Fixed Assets2,2952,1232,8092,7732,8883,0583,5023,3433,4623,075
CWIP 7081,0071,0361,2441,4331,4451,5851,3791,3421,539
Investments 577341056321400000
Trade Receivables4817411,1111,0349621,2741,243918918797
Cash Equivalents 1,1261,2351,4781,6041,082449268292406124
Others Assets4441,037439524544525435645773882
Total Assets 6,6227,5057,9768,8497,9787,5717,7497,3767,6707,075

Cash Flow

(All Figures are in Crores.)
Cash Flow From Operating Activity 1,47635572-26968183649-287413153
PBT 891575289-247-641-300-197916-411-624
Adjustment 134286262303449445483-943554635
Changes in Working Capital 588-345-396-29727880380-143367153
Tax Paid -136-161-84-28-18-41-17-117-97-11
Cash Flow From Investing Activity -852-207-818-68763095-1561,470-201-125
Capex -459-431-492-409-306-270-163-69-211-130
Net Investments -574240373-5204402130000
Others 181-16-69924249615181,539105
Cash Flow From Financing Activity -601-762541,254-769-776-680-1,171-71-315
Net Proceeds from Shares 79086000007480
Net Proceeds from Borrowing -45995671,478-306-619-601-783-737-290
Interest Paid -86-56-88-206-233-259-248-235-190-242
Dividend Paid -164-2450-138000-1-20
Others 28130190121-231101169-152110217
Net Cash Flow 2373-492298-71-499-18612141-287
ROE (%)30.0412.497.07-6.42-21.81-11.43-5.22-9.92-7.77-17.32
ROCE (%)18.9811.256.87-0.31-5.47-2.87-1.11-5.5-1.96-5.88
Asset Turnover Ratio0.770.640.580.480.470.460.370.610.680.58
PAT to CFO Conversion(x)1.750.860.29N/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days5450769893114161856573
Inventory Days778287100918699605661
Payable Days120136135129115161263256233294

Wockhardt Ltd Stock News

Wockhardt Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Wockhardt on 12-Apr-2024 10:20 is ₹565.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2024 10:20 the market cap of Wockhardt stood at ₹8,841.3.
The latest P/E ratio of Wockhardt as of 12-Apr-2024 10:20 is 0.00.
The latest P/B ratio of Wockhardt as of 12-Apr-2024 10:20 is 4.56.
The 52-week high of Wockhardt is ₹630.0 and the 52-week low is ₹162.4.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Wockhardt is ₹1,090 ( Cr.) .

About Wockhardt Ltd

Wockhardt Ltd. is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. It is a true Indian Multi-National Company with a multi-ethnic workforce of many Wockhardt Associates from many different nationalities globally. It has many research centres and several manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. It is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and techno-innovation within Wockhardt.

Business area of the company

The company is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.



  • Outstanding National Citizen Award by National Citizens Guild.
  • Strathmore’s Who’s Who - Social Entrepreneur of the Year.


  • AmeriCares India Spirit of Humanity Award.
  • USA BF Foundation of the Year Award.
  • HEF Award for ‘Outstanding contribution to the teaching community with special reference to Human Values.
  • Best Pharma CSR award at the Pharmaceutical Leadership Summit.


  • IDF - CSR Award.


  • Inclusive India Award under the Corporate category for ‘Best Social Work in the Realm of Primary Healthcare’.
  • IPE CSR Corporate Governance Award.


  • Rajiv Gandhi Global Excellence Award.
  • Rajiv Gandhi Excellence Award.
  • Bharat Gaurav Award.
  • Asian CSR Leadership Awards.
  • CSR Excellence & Leadership Award.
  • Asia Peace Award.


  • Best CSR Project in Healthcare for Mobile 1000 Medical vans - India CSR.
  • Best Community Development Award for Mobile 1000 - World CSR Congress.
  • CSR Professional of the Year - World CSR Congress.
  • Maharashtra Class Owners Association Meritorious Award for valuable contribution in the field of education.
  • Bronze Award for Table Calendar - A.B.C.I (Association of Business Communicators of India).
  • Social Entrepreneur of the Year 2015 - Pharma Leaders.
  • Swachh Bharat Samman - India CSR.
  • Best Environment Friendly Project for Bio-Toilets - Asian CSR Leadership Awards.


  • CSR Leadership Award.
  • Lions CSR Precious Award.
  • Champion of WSIS Prize 2016 - World Summit on the Information Society.
  • Outstanding Leadership Award - Nurturing the Future Foundation.
  • Peace Leader of the Year 2016 - 7th India Leadership Conclave and Indian Affairs Business Leadership Awards 2016.
  • Best Service Award for Significant National Contribution - Institute of Technology & Science.
  • Asia Healthcare Excellence Award - CMO Asia.


  • Excellence Award for Corporate Social Responsibility & Peace Mission - Indian Virtual University for Peace and Education (IVUP).
  • Global NGO Excellence Award for Excellence in Mother & Child Care - World CSR Day.
  • CSR Humanity Award’ by India CSR.
  • Lifetime Achievement Award from the National Institute of Cleanliness Education and Research (NICER).
  • Indian of the Year 2017 (Social Service) by ILC Power Brand.
  • The Rotary Peace Ambassador Award by Rotary.
  • CSR Impact Award by IndiaCSR.
  • Magnificient Man Choice Award with specialization in CEO CSR Excellence from Hopewill International Business Academy.


  • Game Changer Award by The HR Club.
  • Sabarmati Festival Foundation Award for Outstanding Social Work from Sabarmati Festival Foundation.
  • Divyang Ratna Award 2018 by Disable Welfare Trust of India.


  • Mumbai Heroes Award from Blossom Media Pvt Ltd at the Humanity First Conclave.
  • Inspiring Indian Award from Indian Ex Defence Service Employees Chamber of Commerce & Industries (IESECCI).
  • Award for Peace Mobilization from Poddar Foundation at the Insure your Mental Health Conference (Celebrating World Health Day).
  • Inspirational Indian of the Year at the The Mumbai Achievers Awards 2019 by Mumbai Halchal.
  • Bharat Shree Award 2019.
  • Rotary Award from Rotary Club of Mumbai Khar.
  • H F F Excellence Award from Humanity First Foundation.


  • ‘For the Sake of Honour’ Award from Rotary.
  • Excellence in Human Welfare Award from Charity with a Twist, Nargis Dutt Foundation, ECOMO.



  • Wockhardt receives US FDA approval for antibacterial Levofloxacin.
  • Wockhardt launches Prostate drug Flomax in the United States on Day-1.
  • Wockhardt receives US FDA approval for the generic version of Toprol XL, a cardiac drug.


  • Wockhardt launches generic version of Protonix tablets in the US.
  • Wockhardt receives US FDA approval for generic version of Effexor XR capsules.
  • Wockhardt launches three new products in three weeks, in the United States.
  • Wockhardt receives tentative US FDA approval for generic version of Patanol ophthalmic solution.


  • Wockhardt launches generic version of anti-­ulcer drug Prevacid.
  • Wockhardt receives US FDA approval for generic version of Parkinsonism drug Requip XL.
  • Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodon.
  • Wockhardt receives US FDA approval for generic version of Parkinson’s drug Comtan.


  • Wockhardt receives the 'Best Enterprise' award from the Europe Business Assembly.
  • Wockhardt launches generic version of anti-convulsant drug Lamictal XR.


  • Wockhardt’s drug discovery gets a boost with fast track approval by USFDA.


  • Wockhardt Receives ANDA Approval for pain medication Oxycodone liquid.
  • Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA -US FDA grants breakthrough (QIDP) drug discovery status to the New Antibiotic of Wockhardt.


  • Wockhardt sets up its first manufacturing and R&D unit in Middle East.


  • Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 50mg injection of Decitabine, which is used to treat certain forms of cancer.
  • Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 100mg and 400mg tablets of Imatinib Mesylate, which is used to treat many kinds of cancers and tumors.


  • Wockhardt has entered into an agreement with the UK Government to fill finish COVID-19 vaccines.
  • Wockhardt has received approval from Indian drug regulator -- Drug Controller General of India (DCGI) for 2 new antibiotics, EMROK (IV) and EMROK O (Oral), which is used to treat acute bacterial skin and skin structure Infections including diabetic foot infections and concurrent bacteraemia based on the Phase 3 study involving 500 patients in 40 centres across India.
  • Wockhardt has received approval for the transfer of business comprising 62 products and line extensions along with related business assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives; and manufacturing facility in Baddi, Himachal Pradesh, India, where some of the said pharmaceutical products which are being transferred are manufactured and together referred to as the Business Undertaking by way of a slump sale to Dr. Reddy's Laboratories for Rs 1,850 crore as per the terms and conditions specified in the Business Transfer Agreement (BTA).
  • Wockhardt announced COVID-19 vaccine partnership with UK Government.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.